Table 1.
Demographics related to initial surgery.
| Median age at initial surgery (Interquartile range) | 63.6 (60.2–67.6) |
|---|---|
| Median age at recurrence (Interquartile range) | 65.4 (63.1–69.5) |
| Initial Stage | |
| IA | 13 (59.1%) |
| IB | 3 (13.6%) |
| II | 3 (13.6%) |
| IIIA | 2 (9.1%) |
| IIIC1 | 1 (4.5%) |
| Histology | |
| Endometrioid | 16 (72.7%) |
| Serous | 2 (9.1%) |
| Clear Cell | 2 (9.1%) |
| Carcinosarcoma | 2 (9.1%) |
| Lymphovascular Space Invasion | |
| Present | 6 (27.3%) |
| Absent | 16 (72.7%) |
| Microsatellite Instability | |
| Intact | 3 (13.6%) |
| MLH1, PMS2 lost | 5 (22.7%) |
| PMS2 lost | 1 (4.5%) |
| No data reported | 13 (59.1%) |
| Adjuvant Therapy | |
| None | 6 (27.3%) |
| Vaginal Brachytherapy Alone | 5 (22.7%) |
| External Beam Radiation Therapy Alone | 3 (13.6%) |
| Hormonal Therapy Alone | 1 (4.5%) |
| Vaginal Brachytherapy, Chemotherapy | 1 (4.5%) |
| Vaginal Brachytherapy, External Beam Radiation Therapy | 3 (13.6%) |
| External Beam Radiation Therapy, Chemotherapy | 2 (9.1%) |
| Vaginal Brachytherapy, External Beam Radiation Therapy, Chemotherapy | 1 (4.5%) |
Note: N = 22. MLH1 = MLH1 gene. PMS2 = PMS2 gene. Chemotherapy = systemic chemotherapy.